#Sweden #Stockholm #Biopharma #Sobi #Swedish Orphan

Sobi AB Increases Share Count and Voting Rights

On August 29, 2025, Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, announced a significant update regarding its shares and voting rights. The total number of shares now stands at 357,412,837. Among these, 356,000,049 are classified as common shares, while 1,412,788 are categorized as class C shares. This restructuring of shares has resulted in a total of 356,141,327 voting rights.

The issuance of 1,412,788 class C shares was specifically undertaken to meet commitments associated with the company’s long-term incentive programs. These programs are designed to motivate and retain key employees, showcasing Sobi's dedication to fostering talent and innovation within the organization.

Additionally, as of the same date, Sobi holds 11,343,740 of its common shares in its own treasury. The increase in the number of shares is not just a numerical change; it reflects Sobi's strategy for growth and its commitment to enhancing shareholder value.

About Sobi

Sobi is a globally recognized biopharmaceutical company focused on developing innovative treatments for rare diseases. With a workforce of approximately 1,900 employees spread across four continents, Sobi is well-positioned to address the unique challenges faced by patients with rare diseases.

In 2024, the company reported a remarkable revenue figure of SEK 26 billion, emphasizing its robust financial health and market position. Sobi's stock is publicly traded on Nasdaq Stockholm under the ticker STOSOBI.

The recent share increase is part of Sobi’s broader strategy to enhance its market presence and leverage financial instruments for long-term growth. Investors and stakeholders are keenly watching these developments as they could signal future initiatives aimed at expanding Sobi's innovative pipeline and improving patient outcomes.

For more information about the company and its initiatives, stakeholders can visit Sobi's official website and their LinkedIn page.

Conclusion

Sobi’s recent announcement regarding the increase in shares signifies more than just numbers; it represents the company's continual commitment to innovation, growth, and shareholder engagement. As Sobi continues to unlock breakthrough innovations that address the complexities of rare diseases, it sets a prominent example in the biopharmaceutical industry for combining financial strategy with a mission-driven approach to healthcare.